Zhengye Biotechnology Holding (ZYBT) Cash & Equivalents (2023 - 2025)

Zhengye Biotechnology Holding (ZYBT) has 3 years of Cash & Equivalents data on file, last reported at $7.1 million in Q4 2025.

• Cash & Equivalents for Q4 2025 came in at $7.1 million, up 173.97% year-over-year; the trailing twelve-month figure through Dec 2025 was $7.1 million (up 173.97% YoY), and the FY2025 annual result was $7.2 million, up 170.46% from the prior year.
• Cash & Equivalents grew to $7.1 million in Q4 2025 per ZYBT's latest filing, from $2.6 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $7.1 million in Q4 2025 and troughed at $2.6 million in Q4 2024.
• A 3-year average of $4.0 million and a median of $3.2 million in 2023 frame the typical range for Cash & Equivalents.
• The sharpest annual moves came in 2024 and 2025: Cash & Equivalents slumped 31.4% in 2024, then jumped 173.97% in 2025.
• A 3-year view of Cash & Equivalents shows it stood at $3.8 million in 2023, then tumbled by 31.4% to $2.6 million in 2024, then jumped by 173.97% to $7.1 million in 2025.
• Business Quant data shows ZYBT's Cash & Equivalents at $7.1 million in Q4 2025, $2.6 million in Q2 2025, and $2.6 million in Q4 2024.